You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
艾美疫苗(06660.HK):無血清狂犬疫苗III期臨牀試驗取得良好的階段效果
格隆匯 09-20 21:58

格隆匯9月20日丨艾美疫苗(06660.HK)公吿,於2023年8月3日,集團凍幹人用狂犬病疫苗(無血清Vero細胞)在研疫苗(無血清狂犬在研疫苗)III期隨機、盲法、同類疫苗平行對照臨牀試驗,在四川省綿陽市疾病預防控制中心,啟動第一階段18-60週歲30名成年人入組接種工作,在初步評價該30名受試者免後0-7天安全性良好的前提下,於8月10日啟動10-17週歲30名未成年人入組接種工作。於9月18日已完成全程接種後7天安全性觀察,結果表明首劑接種至全程免後7天安全性良好。

狂犬病病毒是一種核糖核苷酸型彈狀病毒,在犬、貓等哺乳動物中傳播的毒力很強。感染該病毒可引起狂犬病,這是一種人獸共患的急性傳染病,臨牀表現為特有的恐水、怕風、嚥肌痙攣、進行性癱瘓等,一旦有症狀出現,病死率接近100%。目前臨牀缺乏治療狂犬病的有效方法,因此暴露後預防至關重要,主要通過接種人用狂犬病疫苗和注射被動免疫製劑。

目前市場上尚沒有無血清狂犬疫苗獲批上市。無血清狂犬在研疫苗,系用狂犬病病毒固定毒株接種無血清Vero細胞製成,具有無血清成分添加的特點,能有效減少產品使用時產生過敏、發熱等不良反應。無血清狂犬疫苗車間已建設完成,設計產能5,000萬劑,若該疫苗成功上市,屆時將為中國乃至全球消除狂犬病助力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account